Clinical Trial Update: A Study of ZYC300 Administered With Cyclophosphamide Pre-Dosing [Phase 1]

View source ↗

Summary

A Phase 1 study of ZYC300 with cyclophosphamide pre-dosing has completed, evaluating its use in breast cancer and ovarian cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Ovarian Cancer

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• ZYC300

Snippet

Sponsor: Eisai Inc. | Conditions: Breast Cancer, Ovarian Cancer | Phase 1 | Status: COMPLETED